Market closed
Olema Pharmaceuticals/$OLMA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Olema Pharmaceuticals
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
Ticker
$OLMA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
88
Website
OLMA Metrics
BasicAdvanced
$461M
-
-$2.29
2.03
-
Price and volume
Market cap
$461M
Beta
2.03
52-week high
$16.78
52-week low
$4.60
Average daily volume
1.4M
Financial strength
Current ratio
7.101
Quick ratio
7.018
Long term debt to equity
0.283
Total debt to equity
0.283
Management effectiveness
Return on assets (TTM)
-33.15%
Return on equity (TTM)
-51.76%
Valuation
Price to book
1.79
Price to tangible book (TTM)
1.79
Price to free cash flow (TTM)
-3.445
Growth
Earnings per share change (TTM)
-1.09%
3-year earnings per share growth (CAGR)
9.96%
What the Analysts think about OLMA
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Olema Pharmaceuticals stock.
OLMA Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
OLMA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
OLMA News
AllArticlesVideos
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·4 weeks ago
Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewsWire·4 weeks ago
Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Olema Pharmaceuticals stock?
Olema Pharmaceuticals (OLMA) has a market cap of $461M as of January 31, 2025.
What is the P/E ratio for Olema Pharmaceuticals stock?
The price to earnings (P/E) ratio for Olema Pharmaceuticals (OLMA) stock is 0 as of January 31, 2025.
Does Olema Pharmaceuticals stock pay dividends?
No, Olema Pharmaceuticals (OLMA) stock does not pay dividends to its shareholders as of January 31, 2025.
When is the next Olema Pharmaceuticals dividend payment date?
Olema Pharmaceuticals (OLMA) stock does not pay dividends to its shareholders.
What is the beta indicator for Olema Pharmaceuticals?
Olema Pharmaceuticals (OLMA) has a beta rating of 2.03. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.